Research programme: anti-ricin antibody therapeutics - AnaptysBio/Edgewood Chemical and Biological Center
Latest Information Update: 16 Jul 2016
At a glance
- Originator AnaptysBio
- Developer AnaptysBio; Edgewood Chemical Biological Center
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ricin poisoning
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Ricin poisoning in USA (Parenteral)
- 16 May 2013 Early research in Ricin poisoning in USA (Parenteral)